MapLight Therapeutics to Participate in Upcoming Investor Conferences
MapLight Therapeutics (Nasdaq: MPLT) announced management will participate in two investor conferences in New York: the RBCCM Global Healthcare Conference on May 19, 2026, and the Jefferies Global Healthcare Conference on June 3, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MapLight Therapeutics (Nasdaq: MPLT) announced management will participate in two investor conferences in New York: the RBCCM Global Healthcare Conference on May 19, 2026, and the Jefferies Global Healthcare Conference on June 3, 2026.
Management will present and host 1x1 meetings; live webcasts and archived recordings will be posted on the company’s Events & Presentations investor page.
Details
News Market Reaction – MPLT
On May 8, the day this news came out, MPLT closed 6.16% below the previous close.
Data tracked by StockTitan Argus for the May 8 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN FRANCISCO and BOSTON, May 08, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conferences:
Event: 2026 RBCCM Global Healthcare Conference (New York, NY)
Date: Tuesday, May 19th
Format: Presenting and hosting 1x1 meetings
Event: 2026 Jefferies Global Healthcare Conference (New York, NY)
Date: Wednesday, June 3rd
Format: Presenting and hosting 1x1 meetings
Where available, access to the live webcasts of these events, as well as archived recordings, will be posted under the “Events & Presentations” page on the Investor section of the company’s website at https://ir.maplightrx.com/news-events/events-presentations.
About MapLight Therapeutics
MapLight Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system disorders. The Company was founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The Company’s discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation. For more information, please visit www.maplightrx.com.
For investor inquiries: investors@maplightrx.com
For media inquiries: media@maplightrx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.